Statininducerede muskelsymptomer

Peter Breining; Christian Sørensen Bork; Lars Erik Bartels; Michael Asger Andersen

doi:10.61409/V03250169

Statininducerede muskelsymptomer

Peter Breining^*, Christian Sørensen Bork, Lars Erik Bartels, Michael Asger Andersen

^*Corresponding author af dette arbejde

Abstract

Cardiovascular disease is a leading cause of death worldwide, and statins are essential for prevention. While muscle symptoms (statin-induced muscle symptoms) are commonly reported, randomised trials suggest a strong nocebo-effect related to treatment with statins. Recent studies have shown that patients can successfully resume statin therapy when informed that their symptoms are not caused by the statin itself. This review finds that clinicians should assess symptoms carefully, rule out alternative causes, and consider dose reduction, statin switching, or intermittent dosing to maintain adherence to prevent cardiovascular events.

Bidragets oversatte titel	Statin-induced muscle symptoms
Originalsprog	Dansk
Artikelnummer	V03250169
Tidsskrift	Ugeskrift for Laeger
Vol/bind	187
Udgave nummer	43
ISSN	0041-5782
DOI	https://doi.org/10.61409/V03250169
Status	Udgivet - 20 okt. 2025

Emneord

Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects
Muscular Diseases/chemically induced
Myalgia/chemically induced
Cardiovascular Diseases/prevention & control

Adgang til dokumentet

10.61409/V03250169Licens: CC BY-NC-ND

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{bbb568f48f3e43b18f79bfaccaec58db,

title = "Statininducerede muskelsymptomer",

abstract = "Cardiovascular disease is a leading cause of death worldwide, and statins are essential for prevention. While muscle symptoms (statin-induced muscle symptoms) are commonly reported, randomised trials suggest a strong nocebo-effect related to treatment with statins. Recent studies have shown that patients can successfully resume statin therapy when informed that their symptoms are not caused by the statin itself. This review finds that clinicians should assess symptoms carefully, rule out alternative causes, and consider dose reduction, statin switching, or intermittent dosing to maintain adherence to prevent cardiovascular events.",

keywords = "Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects, Muscular Diseases/chemically induced, Myalgia/chemically induced, Cardiovascular Diseases/prevention \& control",

author = "Peter Breining and Bork, \{Christian S{\o}rensen\} and Bartels, \{Lars Erik\} and Andersen, \{Michael Asger\}",

note = "Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.",

year = "2025",

month = oct,

day = "20",

doi = "10.61409/V03250169",

language = "Dansk",

volume = "187",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "43",

}

TY - JOUR

T1 - Statininducerede muskelsymptomer

AU - Breining, Peter

AU - Bork, Christian Sørensen

AU - Bartels, Lars Erik

AU - Andersen, Michael Asger

N1 - Published under Open Access CC-BY-NC-BD 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/.

PY - 2025/10/20

Y1 - 2025/10/20

N2 - Cardiovascular disease is a leading cause of death worldwide, and statins are essential for prevention. While muscle symptoms (statin-induced muscle symptoms) are commonly reported, randomised trials suggest a strong nocebo-effect related to treatment with statins. Recent studies have shown that patients can successfully resume statin therapy when informed that their symptoms are not caused by the statin itself. This review finds that clinicians should assess symptoms carefully, rule out alternative causes, and consider dose reduction, statin switching, or intermittent dosing to maintain adherence to prevent cardiovascular events.

AB - Cardiovascular disease is a leading cause of death worldwide, and statins are essential for prevention. While muscle symptoms (statin-induced muscle symptoms) are commonly reported, randomised trials suggest a strong nocebo-effect related to treatment with statins. Recent studies have shown that patients can successfully resume statin therapy when informed that their symptoms are not caused by the statin itself. This review finds that clinicians should assess symptoms carefully, rule out alternative causes, and consider dose reduction, statin switching, or intermittent dosing to maintain adherence to prevent cardiovascular events.

KW - Humans

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors/adverse effects

KW - Muscular Diseases/chemically induced

KW - Myalgia/chemically induced

KW - Cardiovascular Diseases/prevention & control

UR - https://www.scopus.com/pages/publications/105022230014

U2 - 10.61409/V03250169

DO - 10.61409/V03250169

M3 - Review

C2 - 41251244

SN - 0041-5782

VL - 187

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 43

M1 - V03250169

ER -

Statininducerede muskelsymptomer

Abstract

Emneord

Adgang til dokumentet

Andre filer og links

Fingeraftryk

Citationsformater